Paragraph IV Certification

A Paragraph IV (Para IV) certification is a specific legal certification that a generic drug manufacturer must include in an Abbreviated New Drug Application (ANDA) when it wants to launch a generic drug before the expiration of patents listed in the FDA's Orange Book for the innovator drug. HATCH-WAXMAN BACKGROUND: the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) created the ANDA pathway — allowing generics to rely on the innovator's safety and efficacy data without conducting their own clinical trials; in exchange, the generic must certify as to every Orange Book-listed patent; FOUR TYPES OF CERTIFICATION: (I) the patent has expired; (II) the generic will not launch until the patent expires; (III) the generic drug does not come within the scope of the patent; (IV) PARAGRAPH IV — the patent is INVALID or WILL NOT BE INFRINGED by the generic product; PARA IV TRIGGER: filing a Para IV certification is an act of 'artificial infringement' under 35 U.S.C. § 271(e)(2) — the filing of the ANDA with a Para IV certification is itself an infringement of the listed patent (even though the generic has not yet manufactured or sold any product); this allows the patent litigation to occur BEFORE the generic enters the market; NOTICE: the generic must immediately provide written notice to both the NDA holder and the patent owner identifying the specific patent challenged and the factual and legal basis for the challenge; BRANDS' STRATEGY: Orange Book listing is strategic — brands list all potentially relevant patents (composition, formulation, method of use, manufacturing process) to create maximum Para IV litigation opportunity.

THE LITIGATION TIMELINE: (1) GENERIC FILES ANDA WITH PARA IV: generic submits ANDA to FDA claiming Para IV invalidity or non-infringement for one or more Orange Book patents; (2) NOTICE TO BRAND: generic provides written notice to NDA holder and patent owner within 20 days of receiving notice of acceptance of the ANDA; notice must identify the ANDA application, the patents challenged, and the legal and factual basis for the challenge; (3) 45-DAY DECISION WINDOW: the brand has 45 days from receipt of notice to sue for patent infringement; if brand sues within 45 days: FDA approval of the ANDA is automatically stayed for 30 MONTHS (the '30-month stay'); if brand does NOT sue within 45 days: FDA may approve the ANDA after completing its review without a stay; (4) 30-MONTH STAY: the FDA cannot grant final approval of the ANDA for 30 months from the date the brand received the Para IV notice — giving the patent case time to litigate; the 30-month stay can end earlier if the court issues a final judgment of invalidity or non-infringement; the 30-month stay can be extended if the court issues an order stating that it will take longer to resolve the patent case; (5) LITIGATION: the patent infringement case proceeds in federal district court; brands often assert all listed patents; generics assert invalidity (§§ 101, 102, 103, 112) and non-infringement defenses; (6) FDA APPROVAL: after the 30-month stay expires (or court judgment), FDA can approve the ANDA.

FIRST-FILER EXCLUSIVITY: the Hatch-Waxman Act rewards the first generic manufacturer to file a Para IV certification challenging an Orange Book patent with 180 days of market exclusivity — during which no OTHER ANDA applicant can receive final FDA approval; POLICY: the 180-day exclusivity incentivizes generic manufacturers to invest in the research and litigation costs of challenging brand patents; the first filer bears the risk and cost of patent litigation; if successful, the 180-day exclusivity allows the first-filer generic to charge a near-brand price for 180 days before other generics enter; HOW EXCLUSIVITY IS TRIGGERED AND FORFEITED: exclusivity runs from the EARLIER of: (a) the first day of commercial marketing of the first-filer generic; or (b) a court decision of patent invalidity or non-infringement that is not appealed by the brand; FORFEITURE CONDITIONS (enacted by MMA 2003 to prevent 'evergreening' and bottlenecking): first filers can LOSE their 180-day exclusivity if: (1) they fail to market the generic within 75 days of patent court decision or ANDA approval; (2) they enter into an agreement with the brand that is found to be a reverse payment settlement (FTC v. Actavis); (3) they have an ANDA approval withdrawn for failure to satisfy standards; (4) they fail to obtain tentative approval within 30 months of ANDA filing; SHARED EXCLUSIVITY: if multiple generics file on the SAME DAY (patent filing tie), all are deemed 'first applicants' and share the 180-day exclusivity; SIGNIFICANCE: 180-day exclusivity is enormously valuable — for a high-revenue drug, 180 days of near-monopoly pricing can generate hundreds of millions in profits for the first-filer generic.

Orange Book listing is a critical brand strategy for managing generic competition: WHAT IS THE ORANGE BOOK: FDA's Approved Drug Products with Therapeutic Equivalence Evaluations — lists all approved NDAs and their associated patents; generics must certify as to each listed patent in their ANDA; LISTABLE PATENTS: brands can list only patents that: (1) claim the drug substance (active ingredient); (2) claim a drug product (formulation, composition); or (3) claim a method of using the drug for an approved use; manufacturing patents and metabolite patents are NOT listable; STRATEGIC LISTING: brands list patents as quickly as possible after approval to trigger potential Para IV certification requirements for any future generic filers; listing a new patent after an ANDA is pending with Paragraph III certification can reset the certification requirement for that patent; LATE LISTING PROBLEM: if a patent is listed after an ANDA is pending, the generic must amend the ANDA to certify to the newly listed patent; if the generic adds a Para IV certification to the new patent, the 45-day litigation window reopens and a new 30-month stay can be triggered; CITIZEN PETITION TACTIC: brands file citizen petitions with FDA requesting the agency require additional studies or impose labeling requirements on generics — used to delay FDA approval independent of patent litigation; FDA now required to respond to citizen petitions by the date of first generic approval to limit abuse; PATENT DANCE IN BIOLOGICS: the Biologics Price Competition and Innovation Act (BPCIA) creates a similar but more complex 'patent dance' for biosimilars — mandatory information exchange between innovator and biosimilar applicant before litigation.

Para IV litigation is highly strategic — with hundreds of millions of dollars riding on the outcome: BRAND STRATEGIES: (1) file suit within 45 days on ALL Orange Book listed patents — even weak patents — to trigger the 30-month stay and maximize the stay period; (2) seek preliminary injunctions on strong patent claims to extend the stay beyond 30 months if needed; (3) settle with favorable terms (pay-for-delay settlements structured to survive FTC scrutiny after Actavis); (4) list additional patents in the Orange Book during ANDA pendency to trigger additional 30-month stays; (5) file citizen petitions to delay FDA approval independent of the stay; GENERIC STRATEGIES: (1) challenge the weakest patents first with IPR petitions (IPR estoppel risk must be managed); (2) design around formulation and method-of-use patents while challenging composition patents; (3) seek Para IV certification on a narrow indication (skinny label / § viii carve-out) to avoid method-of-use patent infringement; (4) file at-risk launches after 30-month stay if patents are weak — calculate the risk of damages vs. the revenue of early entry; SKINNY LABEL (SECTION viii CARVE-OUT): if a patent claims only a specific METHOD OF USE (indication), the generic can seek approval for only the non-patented uses and carve out the patented method from its label — avoiding Para IV certification for that patent; this is the 'skinny label' strategy; GSK v. Teva (Fed. Cir. 2021) created uncertainty about induced infringement liability even with carve-outs; AT-RISK LAUNCH: generic launches while patent litigation is still pending; if brand wins, generic owes damages (royalties); for weak patents, at-risk launch can be profitable even with damage exposure.